Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

Genmab (GMAB) is a stock many investors are watching right now. GMAB is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Another notable valuation metric for GMAB is its ...

Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded. During this telephone conference, you may ...

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

Genmab A/S Price Performance Shares of GMAB opened at $23.12 on Wednesday. The firm has a market capitalization of $15.30 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 0.68 and ...

In this article, we are going to take a look at where Genmab (NASDAQ:GMAB) stands against other most profitable growth stocks to invest in. After the September inflation report, the market did ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...